| ADXS Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the ADXS shares outstanding history going back to 7/15/2013:
Also see: ADXS Market Cap History ADXS YTD Return |
ADXS Shares Outstanding History — Advaxis Share Count Over Time
As of 9/7/2021 Advaxis has 145.64 million ADXS shares outstanding. Investors often track the ADXS shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows ADXS share count trends over time, with 35 historical shares outstanding datapoints presented, dating back to 7/15/2013.
| ADXS Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADXS Historical Shares Outstanding: +112.02% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADXS Stock Price Chart |
| About Ayala Pharmaceuticals Inc |
| Ayala Pharmaceuticals is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab). We show 35 historical shares outstanding datapoints in our coverage of ADXS's shares outstanding history. Understanding the changing numbers of ADXS shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ADXS versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ADXS by allowing them to research ADXS shares outstanding history as well as any other stock in our coverage universe. |
| ADXS Current Stock Quote |
Quotes delayed 20 minutes  Free ADXS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| ADXS Share Performance |
| Shares Outstanding Peers |
| Advaxis (ADXS) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
ADYX Shares Outstanding History AEMD Shares Outstanding History AERI Shares Outstanding History AEZS Shares Outstanding History AFIB Shares Outstanding History AGEN Shares Outstanding History AGIO Shares Outstanding History AGL Shares Outstanding History AGLE Shares Outstanding History AGN Shares Outstanding History More Healthcare companies » |
ADXS Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
